Stanford professor Russ Altman acknowledges that startups often fear regulators, but insists that in the biotech space, the FDA is keen to work with companies to bring products to market and advise startups as part of an open dialogue. In the context of AI-driven drug development, GSK senior VP and Global Head of AI/ML Kim Branson adds, an evolving conversation between industry and government will lead to new ways of ensuring the safe delivery of cutting-edge therapies.
Related
Luke Sykora,
Stanford University
Starting Up in a Downturn
An Entrepreneurial Thought Leaders mini-guide for aspiring founders facing a troubled economy.
Josh Makower, MD,
Stanford Byers Center for Biodesign
The Biodesign Innovation Process [Entire Talk]
Innovation isn’t random – it’s a process that can be learned, improved, and effectively deployed to solve specific problems.
Josh Makower, MD,
Stanford Byers Center for Biodesign
The Biodesign Innovation Process [Entire Talk]
Innovation isn’t random – it’s a process that can be learned, improved, and effectively deployed to solve specific problems.
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
